De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.

doi:10.1038/s41467-022-29104-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.

Nature communications - 17 Mar 2022

Gandhi Shiv, Klein Jonathan, Robertson Alexander J, Peña-Hernández Mario A, Lin Michelle J, Roychoudhury Pavitra, Lu Peiwen, Fournier John, Ferguson David, Mohamed Bakhash Shah A K, Catherine Muenker M, Srivathsan Ariktha, Wunder Elsio A, Kerantzas Nicholas, Wang Wenshuai, Lindenbach Brett, Pyle Anna, Wilen Craig B, Ogbuagu Onyema, Greninger Alexander L, Iwasaki Akiko, Schulz Wade L, Ko Albert I

Abstract excerpt

SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alanine

Share to Antibodies, Monoclonal, Humanized

Share to COVID-19 Drug Treatment

Share to Immunocompromised Host

Share to Mutation

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Source

Open in PubMed Open full text

Identifiers

PMID: 35301314
DOI: 10.1038/s41467-022-29104-y
PMCID: PMC8930970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.PMID 35301314Read ↗

<i>De novo</i> emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case reportSemantic proximity Read ↗

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.Semantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Semantic proximity Read ↗

<i>In vitro</i> evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2Semantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infectionsSemantic proximity Read ↗

Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infectionSemantic proximity Read ↗

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug ResistanceSemantic proximity Read ↗

The impact of remdesivir on SARS-CoV-2 evolution in vivo.Semantic proximity Read ↗

Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivirSemantic proximity Read ↗

Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.Semantic proximity Read ↗

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms.Semantic proximity Read ↗

Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.